Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He will be in a tux when his proponents buy his IPO based on the fantasy clinicals trials in Mexico.
What suit will Dan wear when his best friend, co founder of RMOnopoly, co founder of wund, co founder of Nev Bio, Jon Laub gives Dan the nepotism award...I mean Bio CEO of the year award? Too bad it's not the prison orange suit.
And why stop at bio CEO of the year? Why not up the ante. DAN certainly deserves a better award from his close friend, colleague, co founder... I say we start a petition to increase the award to bio CeO of the decade. No ...still not good enough. Surely with all the people Dan has healed and all the jobs he has created and all the good he has done for his community and all the high flying bio tech companies he has founded he deserves CEO of the century.
How many nominations were there?
What was the selection criteria?
Who was on the committee to select the winner?
Since it's in Vegas, let me give you my wager...
1 nomination - Just Dan. Likely nominated by a friend or family member.
Selection criteria was nil as it was likely predetermined.
Who was on the committee? Again likely friends, family and Dan himself.
WAY TO GO DAN! YOU EARNED IT!
HAHAHHAHA
Biotech CEO of the year... haven't you heard?
A prior judgment against Montano for 2.5 million does not go away. Please buy Montano's IPO. He is such a great business man and he has pioneered the clinicals in Mexico, what a hero.....
Who celebrates a "victory" when you have already lost the war to CVBT/VT. I guess Dan Montano wants that participation trophy to show his kids how it's done LOL
In my experience with lawyers, they will not take a case and begin work without a retainer being paid. And since Mr. Cannaday is a "partner" with one of the largest law firms in the country, we have to assume this is true. Once the retainer is paid they will work until the money from the retainer is used up and then request another retainer. This scenario continues until the case is completed. So one has to assume somewhere along the lines of this case there had to be a disagreement on fee's or performance, which prompted VT not to pay. From what I understand, this is not uncommon. Also, just because Mr. Cannaday withdrew from the case does not mean he won't be paid. I'm sure there are negotiations going on to get him paid and this will no longer be a talking point for the non supporters.
So let's summarize: the Montano supporters, 5 years and over 800 funny claims later, have been saying it's the end for CVBT/VT, but yet here we are. Is it safe to say that Dan Montano and his cronies are still jaded they lost CVBT/VT to an Oil and Gas guy?? I think so!
Well...at least they have money shows and retirement homes to steal from to keep their pipe dreams alive. OH, and don't forget Montano will be receiving an award being recognized as Biotech Entrepreneur of the Year (HAHAHAHAHA) tomorrow, July 15 in Las Vegas!
CVBT/VT LAWYERS ADMIT CVBT/VT IS WORTHLESS IN FEDERAL COURT
The truth about Cardiovascular Biotherapeutics/Venturis Therapeutics is coming out as a result of the lawsuit they have filed against our former administration.
Our own lawyers were forced to withdraw themselves from the case as a result of Cardiovascular Biotherapeutics'/Venturis Therapeutics' inability to pay the company's lawyers.
As bad as that may sound, this is not all, the company's lawyer then went on to state: Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.
Our own lawyers admitted in Federal District Court the incompetence of our administration. We are a worthless company. The United States Federal Court states it in their records, our own lawyers state it, our former administrative members say it.
Cardiovascular Biotherapeutics/Venturis Therapeutics is officially worthless.
"it has become evident that there are currently no assets or revenue streams from which payments can be made."
It gets worse. Not only did our company's lawyers withdraw themselves from Cardiovascular Biotherapeutics/Venturis Therapeutics' lawsuit in federal court, they have also emphasized how defunct Venturis Therapeutics/CVBT truly is in a statement to the United States Federal Court. I have posted another excerpt:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 23-25 read as follows:
"Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."
"...unpaid fees in excess of $200,000..."
I was able to get my hands on some court documents and was able to find more about why CVBT/VT's lawyers have withdrawn themselves from their suit in Federal District Court. It appears that we did not have enough money to pay them. I have posted an excerpt here:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 15-17 are as follows:
Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.
"Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement."
I have managed to obtain some court documents further ellaborating why our company's lawyer has withdrawn himself from the case. I have posted an excerpt here:
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC.,
formerly known as CARDIOVASCULAR
BIOTHERAPEUTICS, INC.
Claimant,
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN
THE ALTERNATIVE, MOTION TO
WITHDRAW AS COUNSEL FOR
VENTURIS THERAPEUTICS, INC.
Page 3, Line 16 Reads as follows:
However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.
$1,100,000 awarded to Daniel C. Montano by the US Federal Court against CVBT/VT
The United States Federal court has confirmed Daniel C. Montano's $1.1 million dollar judgement against CVBT/VT as a result of their fraudulent and frivolous lawsuit claiming that Daniel C. Montano's IP was not his.
The US Federal Court not only confirmed that Daniel C. Montano has a $1 million dollar (non-off-settable) judgement against CVBT/VT, but that Daniel C. Montano and Zhittya Genesis Medicine own all of their IP.
Daniel C. Montano announces that the US Federal Court has confirmed his IP
The United States Federal Court has confirmed the ruling in favor of Daniel C. Montano citing that Dan Montano owns all of the IP that he and his company, Zhittya Genesis Medicine are developing.
The United States Federal Court's confirmation comes as a result of Cardiovascular Biotherapeutics/ Venturis Therapeutics' own management team testifying in favor of Daniel C. Montano, stating that the IP that Dan Montano and Zhittya Genesis Medicine have been developing are 100% theirs.
Daniel C Montano Announces His Victory over CVBT/VT
Despite years of fraudulent and frivolous lawsuits it appears that Daniel C Montano is now victorious over the crooks that run Cardiovascular Biotherapeutics/Venturis Therapeutics.
Daniel C. Montano has been awarded an over $1 million dollar judgment against CVBT/VT as a result of the frivolous lawsuit that they had originally filed.
Daniel C. Montano's more than $1,000,000 dollar judgement against Cardiovascular BioTherapeutics/Venturis Therapeutics has been confirmed by the United States Federal Court System.
Dan Montano's clear victory over CVBT/VT could result in a forced debtors exam against CVBT/VT in order for Montano to collect on his judgement.
Daniel C Montano has announced that he has won a $1 million dollar judgement against CVBT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C Montano announces that he wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT, within the next 30 days the shareholders will know that CVBT/VT has no financial viability and is an empty shell of a company.
I fear that Dan Montano will seize all of the assets, including IP, that CVBT has and will sue the CVBT/VT directors for their actions.
DEBTORS EXAM FOR CARDIOVASCULAR BIOTHERAPEUTICS (CVBT)/VENTURIS THERAPEUTICS
Rumor has it that as a result of Dan Montano's court victory, which has given him a judgment of a $1 million dollar claim against Venturis Therapeutics, confirmed by the Federal Court, that Dan Montano will be seeking a debtors exam for CVBT in the month of May. I am worried that this debtors exam will reveal the true financial position of CVBT/Venturis Therapeutics and make the CVBT directors liable.
How will this debtor's exam affect the future of CVBT? Will there be a future for CVBT following this major legal victory for Daniel C. Montano? Where will CVBT get the $1 million dollars to pay Mr. Dan Montano?
THE UNITED STATES FEDERAL COURT HAS CONFIRMED DAN MONTANO'S ONE MILLION DOLLAR CLAIM AGAINST CVBT/VENTURIS THERAPEUTICS
Furthermore, with Zhittya Genesis Medicine and Mrs. Montano being ENTIRELY DISMISSED from the lawsuits that Venturis brought fourth there is a clear path for Mr. Daniel Montano to forcibly collect on his 1 million dollar claim. Venturis is at the hands of Dan Montano! Why were we not made aware of this? Why is our administration so quick to announce when lawsuits are filed but not when we are miserably defeated and punished for our defeat?
I worry that Mr. Montano will wipe Venturis off the face of the map with his new ability to forcibly collect on his one million dollar award which has been confirmed by the United States Federal Court.
Daniel C. Montano wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021.
Dan Montano's Clear Victory over CVBT
CardioVascular BioTherapeutics/Venturis Therapeutics has lost yet another court battle to Dan Montano. As a result of this miserable defeat, the US Federal Court has confirmed Dan Montano's $1 million dollar judgment against CVBT/Venturis Therapeutics despite bringing on the case themselves!
Despite what individuals say on this page, there is no right of offset to this matter! Dan Montano's $1 million dollar judgement has no offset. The Court Records clearly indicate the Dan Montano's $1 million dollar judgement. Those same Court Records DO NOT INDICATE THAT VENTURIS THERAPEUTICS IS OWED ANYTHING FROM DAN MONTANO. There is no right of offset. We can only hope that Dan Montano will not initiate a debtor's exam.
Hopefully he will push his IPO so Venturis can get the 1.7 mill. I am sure the trials in Mexico are progressing!!!
Look for another smoke and mirrors press release by Montano and his company of family members.
I agree and that was the point I was trying to make. To value the patents would be speculative. The value is there IMP once trials commence and the science is proven. Does not say at some point major pharma steps in and buys or partners with Venturis.
What suit will Dan wear when his best friend, co founder of RMOnopoly, co founder of wund, co founder of Nev Bio, Jon Laub gives Dan the nepotism award...I mean Bio CEO of the year award? Too bad it's not the prison orange suit.
And why stop at bio CEO of the year? Why not up the ante. DAN certainly deserves a better award from his close friend, colleague, co founder... I say we start a petition to increase the award to bio CeO of the decade. No ...still not good enough. Surely with all the people Dan has healed and all the jobs he has created and all the good he has done for his community and all the high flying bio tech companies he has founded he deserves CEO of the century.
How many nominations were there?
What was the selection criteria?
Who was on the committee to select the winner?
Since it's in Vegas, let me give you my wager...
1 nomination - Just Dan. Likely nominated by a friend or family member.
Selection criteria was nil as it was likely predetermined.
Who was on the committee? Again likely friends, family and Dan himself.
WAY TO GO DAN! YOU EARNED IT!
HAHAHHAHA
So let's summarize: the Montano supporters, 5 years and over 800 funny claims later, have been saying it's the end for CVBT/VT, but yet here we are. Is it safe to say that Dan Montano and his cronies are still jaded they lost CVBT/VT to an Oil and Gas guy?? I think so!
Well...at least they have money shows and retirement homes to steal from to keep their pipe dreams alive. OH, and don't forget Montano will be receiving an award being recognized as Biotech Entrepreneur of the Year (HAHAHAHAHA) tomorrow, July 15 in Las Vegas!
It doesn't take a rocket scientist to know the patents aren't worth anything right now. However, once VT becomes liquid and begins to move forward with trials, this is when the patents absolutely become valuable.
In my experience with lawyers, they will not take a case and begin work without a retainer being paid. And since Mr. Cannaday is a "partner" with one of the largest law firms in the country, we have to assume this is true. Once the retainer is paid they will work until the money from the retainer is used up and then request another retainer. This scenario continues until the case is completed. So one has to assume somewhere along the lines of this case there had to be a disagreement on fee's or performance, which prompted VT not to pay. From what I understand, this is not uncommon. Also, just because Mr. Cannaday withdrew from the case does not mean he won't be paid. I'm sure there are negotiations going on to get him paid and this will no longer be a talking point for the non supporters.
If we use Dan Montano accounting rules I disagree.
Barry Canaday may be a lawyer but is he an accountant? Is he a financial professional? Is he qualified to provide valuation of assets? The answer is no.
Move along and find another place to lay your hopes and dreams because this one will not fly. Keep grasping at straws.
You are incorrect, Dentons made it extremely clear that there are no assets of value at Venturis and thus the patents have no value. Let me quote from Barry Cannaday's sworn statement to the U.S. Federal Court: "Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."
If you are correct and any of Venturis's assets have any meaningful value and therefore could have been used to pay Dentons, contrary to the sworn statement of Mr. Cannaday, he will have made a false statement to the court and would be subject to disbarment.
So let's summarize: A partner at one of the largest law firms in the country has stated to the U.S. Federal Court that the assets of Venturis Therapeutics are worthless. In contrast, an anonymous supporter of the company (who does not identify themself as Mr. Cannaday has) is saying that Mr. Cannaday's statement is false, without offering any evidence.
There was never any statement about the patents value. Speculation at best on what the value of the patents are. Once Montano pays the difference in the judgements, Venturis will has assets in the form of 1.7 mill.
If the patents had any value whatsoever (and they don't), why did Venturis's own law firm--the one that all but certainly filed the IP and certainly knows what the patents are--state to the U.S. Federal Court, "Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made"?
Venturis's own law firm is publicly stating that they believe these patents are worthless--which happens to also be the opinion of anyone qualified who is not a part of the company's leadership team.
If the patents had any value whatsoever, why wouldn't Dentons have gone after them for payment of its $200,000+ in unpaid invoices?
No revenue stream at this time but the owner of patents. Montano has no revenue stream and no patents. I back Venturis.
THE END OF VENTURIS/CVBT: The court filing by Venturis's lawyer
So many lies have been promoted in public by anonymous pro-company individuals about Venturis Therapeutics. This declaration by Venturis Therapeutics's own lawyer, withdrawing from representation on April 12, 2021, puts every last one of them to rest. Here it is in its entirety:
DECLARATION OF BARRY F. CANNADAY IN SUPPORT OF MOTION TO WITHDRAW
I, Barry F. Cannaday, declare as follows in support of this Motion to Withdraw as an Attorney for Venturis Therapeutics, Inc. (“Venturis”) in the matter styled Daniel C. Montano and Dr. John W. Jacobs vs. Venturis Therapeutics, Inc., Case No. 2:20-cv-01410-GMN-BNW originally filed in the United States District Court for the District of Nevada, but which was closed on January 21, 2021 (the “Previously Closed Case”):
1. I am an attorney duly licensed to practice before all Courts in the State of Texas and I was admitted to practice Pro Hac Vice in the Previously Closed Case on behalf of Venturis on August 18, 2020. I have been a partner in the law firm of Dentons US, LLP since 2009.
2. Venturis initially agreed to retain Barry F. Cannaday in connection with the arbitration that was filed by Venturis against Mr. Montano and Dr. Jacobs (“Counter-Claimants”) on July 19, 2018. Following the issuance of the Arbitrator’s Final Award in that Arbitration on July 20, 2020, Counter-Claimants filed an Application for Order Confirming Arbitration Award in this Court on July 29, 2020. Barry F. Cannaday agreed to continue to represent Venturis in connection with the proceedings in this Court relating to Counter-Claimants attempts to confirm the Arbitration Award. This Court confirmed the Arbitration Award on January 25, 2021 and this case was thereafter closed on January 25, 2021.
3. On April 8, 2021 counsel for Counter-Claimants provided Barry F. Cannaday with copies of post-judgment Interrogatories and Requests for Production,. However, Barry F. Cannaday has not agreed to represent Venturis in any connection with post-judgment collection matters. Mr. Cannaday considered his representation of Venturis in this matter completed when this case was closed on January 25, 2021.
4. Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.
5. Barry F. Cannaday performed his obligations as counsel for Venturis in the Previously Closed Case and in the underlying Arbitration in a skillful and diligent manner. However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.
6. Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.
7. Barry F. Cannaday and Venturis have maintained a good working relationship throughout these proceedings. As such, the present Motion to Withdraw is not the result of any differences between Barry F. Cannaday and the client, but instead is the result of the inability of Venturis to meet its financial obligations to Dentons.
8. Defendant’s address is: 10455 Markison Road, Dallas, Texas 75238 and Barry F. Cannaday certifies that Venturis will be served with a copy of this Motion to Withdraw.
9. I personally visited with Jon Ross, Secretary and a Member of the Board of Directors of Venturis on Thursday, April 8, 2021 and advised him of my intention to file this notice and motion. Mr. Ross stated that Venturis had no objection to this Motion to Withdraw. I declare under penalty of perjury of the laws of the State of Nevada that the foregoing is true and correct.
Executed this 12th day of April, 2021.
/s/ Barry F. Cannaday
Barry, F. Cannaday, Esq.
DENTONS US LLP
2000 McKinney Ave
Suite 1900
Dallas, Texas 75201
Telephone: (214) 259-1855
Facsimile: (214) 259-0910
So this is it, folks. Venturis's own lawyers says that the company has only worthless assets and no revenues, and that they've stiffed his firm to a figure north of $200,000. I believe this is the final word on this dead company, led to its demise in my opinion by crooks and charlatans, all of them.
Maybe there is cash involved so Montano can pay his debt to Venturis
Daniel C Montano is winning awards again. He is a leading light and serial entrepreneur in the biotech sector. Well done Dan. We are all busy buying tickets to come to the July dinner so we can applaud your amazing achievement !!
https://www.globenewswire.com/news-release/2021/06/17/2249239/0/en/Mr-Daniel-C-Montano-CEO-is-recognized-as-Biotech-Entrepreneur-of-the-Year-and-Dr-Marc-Kahn-as-Medical-Professional-of-the-Year-by-the-Nevada-Biotechnology-Health-Science-Consortium.html et
Daniel C Montano - he does ! That is all he knows.
Who celebrates a "victory" when you've already lost the war to CVBT/VT. I guess Dan Montano wants that participation trophy to show his kids how it's done LOL
CVBT/VT LAWYERS ADMIT CVBT/VT IS WORTHLESS IN FEDERAL COURT
The truth about Cardiovascular Biotherapeutics/Venturis Therapeutics is coming out as a result of the lawsuit they have filed against our former administration.
Our own lawyers were forced to withdraw themselves from the case as a result of Cardiovascular Biotherapeutics'/Venturis Therapeutics' inability to pay the company's lawyers.
As bad as that may sound, this is not all, the company's lawyer then went on to state: Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made.
Our own lawyers admitted in Federal District Court the incompetence of our administration. We are a worthless company. The United States Federal Court states it in their records, our own lawyers state it, our former administrative members say it.
Cardiovascular Biotherapeutics/Venturis Therapeutics is officially worthless.
"it has become evident that there are currently no assets or revenue streams from which payments can be made."
It gets worse. Not only did our company's lawyers withdraw themselves from Cardiovascular Biotherapeutics/Venturis Therapeutics' lawsuit in federal court, they have also emphasized how defunct Venturis Therapeutics/CVBT truly is in a statement to the United States Federal Court. I have posted another excerpt:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 23-25 read as follows:
"Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."
"...unpaid fees in excess of $200,000..."
I was able to get my hands on some court documents and was able to find more about why CVBT/VT's lawyers have withdrawn themselves from their suit in Federal District Court. It appears that we did not have enough money to pay them. I have posted an excerpt here:
UNITED STATES DISTRICT COURT DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC., formerly known as CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Claimant
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN THE ALTERNATIVE, MOTION TO WITHDRAW AS COUNSEL FOR VENTURIS THERAPEUTICS, INC.
Page 3 Lines 15-17 are as follows:
Further, as of March 31, 2021, Venturis owed Mr. Cannaday’s law firm, Dentons US LLP (“Dentons”), unpaid fees in excess of $200,000 for representation in this Previously Closed Case and for representation in the underlying arbitration.
"Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement."
I have managed to obtain some court documents further ellaborating why our company's lawyer has withdrawn himself from the case. I have posted an excerpt here:
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA
Venturis THERAPEUTICS, INC.,
formerly known as CARDIOVASCULAR
BIOTHERAPEUTICS, INC.
Claimant,
Case No. 2:20-cv-01410-GMN-BNW
NOTICE OF WITHDRAWAL AND IN
THE ALTERNATIVE, MOTION TO
WITHDRAW AS COUNSEL FOR
VENTURIS THERAPEUTICS, INC.
Page 3, Line 16 Reads as follows:
However, Venturis has been rendered incapable of paying Mr. Cannaday’s law firm in accordance with the terms of its agreement.
$1,100,000 awarded to Daniel C. Montano by the US Federal Court against CVBT/VT
The United States Federal court has confirmed Daniel C. Montano's $1.1 million dollar judgement against CVBT/VT as a result of their fraudulent and frivolous lawsuit claiming that Daniel C. Montano's IP was not his.
The US Federal Court not only confirmed that Daniel C. Montano has a $1 million dollar (non-off-settable) judgement against CVBT/VT, but that Daniel C. Montano and Zhittya Genesis Medicine own all of their IP.
Daniel C. Montano announces that the US Federal Court has confirmed his IP
The United States Federal Court has confirmed the ruling in favor of Daniel C. Montano citing that Dan Montano owns all of the IP that he and his company, Zhittya Genesis Medicine are developing.
The United States Federal Court's confirmation comes as a result of Cardiovascular Biotherapeutics/ Venturis Therapeutics' own management team testifying in favor of Daniel C. Montano, stating that the IP that Dan Montano and Zhittya Genesis Medicine have been developing are 100% theirs.
Daniel C Montano Announces His Victory over CVBT/VT
Despite years of fraudulent and frivolous lawsuits it appears that Daniel C Montano is now victorious over the crooks that run Cardiovascular Biotherapeutics/Venturis Therapeutics.
Daniel C. Montano has been awarded an over $1 million dollar judgment against CVBT/VT as a result of the frivolous lawsuit that they had originally filed.
Daniel C. Montano's more than $1,000,000 dollar judgement against Cardiovascular BioTherapeutics/Venturis Therapeutics has been confirmed by the United States Federal Court System.
Dan Montano's clear victory over CVBT/VT could result in a forced debtors exam against CVBT/VT in order for Montano to collect on his judgement.
Daniel C Montano has announced that he has won a $1 million dollar judgement against CVBT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C Montano announces that he wins a ONE MILLION DOLLAR JUDGEMENT against Venturis Therapeutics(fka CVBT)
In an unfortunate turn of events for our administration, the arbitration case initiated by Venturis Therapeutics against Mr. Daniel Montano has resulted in Dan Montano winning a one million dollar judgement against Venturis Therapeutics as well as attorneys' fees and costs; confirmed by the US Federal Court.
Mr. Montano is now pursuing the involuntary collections of his judgment against Venturis, which will include a judgment debtor discovery against Venturis Therapeutics so that Mr. Montano can seize the assets of the company and satisfy the terms of his judgement.
Even worse for Venturis: Other litigation initiated by Venturis against Mrs. Montano and Zhittya Genesis Medicine (commonly referred to as Zhittya) has been DISMISSED by the Nevada State courts.
THIS IS A CLEAR VICTORY FOR DAN MONTANO AND ZHITTYA. After this judgement I will be surprised if Venturis Therapeutics makes it through 2021
Daniel C. Montano announced that he has won a judgement against CVBT/VT
Daniel C. Montano has announced that he has won a $1 million dollar judgement against Cardiovascular Biotherapeutics/Venturis Therapeutics confirmed by the US Federal Court. The judge dismissed all of CVBT/VT's claims against Dan Montano. Our current administration's takeover in 2014 has resulted in CVBT/VT suing Daniel C. Montano 10 different times to stop him from developing FGF-1. Each time CVBT/VT has lost to Daniel C. Montano, resulting in astounding victories for Dan Montano.
CVBT/VT's three biotech experts all independently testified that Dan Montano was innocent from the fraudulent claims made by CVBT/VT management.
The most recent court judgement has not only given Daniel C. Montano the ability to actively pursue the fraudulent claimants in order to satisfy his $1 million dollar judgement, but also has given Dan Montano the ability to actively focus on developing FGF-1 at Zhittya Genesis Medicine which has now initiated two Phase I Clinical Trials in Parkinson's Disease and ALS.
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT, within the next 30 days the shareholders will know that CVBT/VT has no financial viability and is an empty shell of a company.
I fear that Dan Montano will seize all of the assets, including IP, that CVBT has and will sue the CVBT/VT directors for their actions.
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3647
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |